康弘药业依帕司他片获药品注册证书

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Group 1: Product Information - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [1] - Clinical studies have shown that Ipatasertib can inhibit the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, improving subjective symptoms and neurological dysfunction compared to the control group [1]